Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  • 182 Accesses

  • 72 Citations


The inhibition of soluble catechol-O-methyltransferase (S-COMT) in red blood cells (RBCs) by entacapone, and the pharmacokinetics of entacapone after single oral (5–800 mg) and IV (25 mg) doses have been examined in an open study in 12 healthy young male volunteers.

Oral entacapone dose-dependently decreased the activity of S-COMT in RBCs with a maximum inhibition of 82% after the highest dose (800 mg). The inhibition of S-COMT in RBCs was reversible and the activity recovered within 4–8 h.

Entacapone showed linear pharmacokinetics over the dose range studied: Cmax and AUC were correlated with the dose of the drug. Oral absorption of entacapone was fast, with a tmax ranging from 0.4 to 0.9 h, depending on the dose. Systemic availability of entacapone varied between 30 and 46%. Entacapone was rapidly eliminated by metabolism with a half-life of 0.27–0.30 h after oral doses of 5 to 50 mg. After doses from 100 to 800 mg the disposition was best described by two phases with a t1/2α of 0.27–0.37 h and t1/2β of 1.59–3.44 h.

Over the dose range studied, the single oral and IV doses of entacapone were well tolerated. No haematological, biochemical or haemodynamic adverse effects were seen.

The results show that entacapone is an orally effective and reversible COMT inhibitor in man and has simple, linear pharmacokinetics.

This is a preview of subscription content, log in to check access.


  1. Ball P, Knuppen R, Breuer H (1971) Purification and properties of catechol-O-methyltransferase of human liver. Eur J Biochem 21: 517–525

  2. Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives — synthesis and structure activity studies. Helv Chim Acta 72: 952–968

  3. Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Lindén I-B, Männistö PT, Kaakkola S, Pohto P (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase (COMT) inhibitors. J Med Chem 32: 841–846

  4. Calne DB, Reid JL, Vakil SD (1972) Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 14: 386–389

  5. Gancher ST, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating patients. Neurology 37: 940–944

  6. Gervas J, Muradas B, Bazan E, Aguado E, de Yebenes J (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282

  7. Guldberg HC, Marsden CA (1975) Catechol-O-methyltransferase: Pharmacological aspects and physiological role. Pharmacol Rev 27: 135–206

  8. Kaakkola S, Wurtman R (1993) Effects of catechol-O-methyltransferase inhibitors and 1–3, 4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137–144

  9. Karlsson M, Wikberg T (1992) Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 10: 593–600

  10. Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone, on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145–156

  11. Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from postinfusion blood curves obtained after iv infusion. J Pharm Sci 59: 53–55

  12. Markwell MAK, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 206–210

  13. Metzler CM, Weiner DL (1989) PCNONLIN Version 30 Software for the statistical analysis of nonlinear models on micros, PCNONLIN user guide. Statistical Consultants Inc, Lexington, Ky

  14. Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317–323

  15. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S (1992) Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT-inhibitors. Prog in Drug Res 39: 291–350

  16. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T (1993) Effects of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45: 419–423

  17. Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S (1988) Catechol-O-methyltransferase in human and rat small intestine. Life Sci 42: 2609–2614

  18. Nissinen E, Lindén I-B, Schultz E, Photo P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedeberg's Arch Pharmacol 346: 262–266

  19. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21: 584–588

  20. Nutt JG, Woodward WR, Stone CK, Beckner RM, Carter JH, Gancher ST, Hammerstad JP, Gordin A (1994) Effects of peripheral catechol-O-methyltransferase (COMT) inhibitor on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (in press)

  21. Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271

  22. Reches A, Miekle L, Fahn S (1982) 3-O-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888

  23. Ruottinen H, Rinne UK (1993) Effect of COMT inhibition with entacapone on clinical response, pharmacokinetics and metabolism of levodopa in Parkinson's disease. Neurology 43 [Suppl 2]: 685

  24. Schultz E, Nissinen E, Kaakkola S (1989) Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr 3: 64–67

  25. Schultz E, Tarpila S, Bäckström A-C, Gordin A, Nissinen E, Pohto P (1991) Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur J Clin Pharmacol 40: 577–580

  26. Törnwall M, Männistö PT (1993) Effects of three types of catechol O-methylation inhibitors on 1–3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur J Pharmacol 250: 77–84

  27. Wade L, Katzman R (1975) 3-O-methyldopa inhibition of L-dopa at the blood-brain barrier. Life Sci 17: 131–136

  28. Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, Von Sprecher G (1990) CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn-Schmiedeberg's Arch Pharmacol 342: 305–311

  29. Weinshilboum RM (1978) Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci 22: 625–630

  30. Wikberg T, Vuorela A, Ottoila P, Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in the rat and in humans. Drug Metab Dispos 21: 81–92

Download references

Author information

Correspondence to T. Keränen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Keränen, T., Gordin, A., Karlsson, M. et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46, 151–157 (1994). https://doi.org/10.1007/BF00199880

Download citation

Key words

  • Entacapone
  • catechol-O-methyltransferase
  • pharmacokinetics
  • healthy volunteers
  • adverse effects
  • metabolism